The effect of IDO as an immunosuppressive, pro-tumour factor has been queried due to a lack of efficacy reported in a recent phase III clinical trial combining the potent IDO inhibitor epacadostat with αPD-1 therapy in patients with non-resectable and metastatic melanoma [89]. Here, IDO1 is linked to metastatic melanoma.